{
  "pmcid": "5831461",
  "abstract": "300-word version:\n\nTitle: Intraoperative Dexmedetomidine and Postoperative Delirium: A Randomised Controlled Trial\n\nBackground: Postoperative delirium is prevalent in 10% to 60% of elderly patients undergoing major surgery, contributing to prolonged hospital stays and increased mortality. While dexmedetomidine sedation in critical care units has been associated with reduced delirium, its intraoperative efficacy is less understood.\n\nMethods: This multicenter, double-blind, randomized, placebo-controlled trial evaluated the effect of intraoperative dexmedetomidine on postoperative delirium in elderly patients (>68 years) undergoing major elective noncardiac surgery. Participants were randomized to receive dexmedetomidine (0.5 Âµg/kg/h) or saline placebo during surgery and for 2 hours postoperatively. The primary outcome was the incidence of postoperative delirium, assessed daily. Secondary outcomes included postoperative cognitive decline. Randomization was computer-generated, with allocation concealed via sealed envelopes. Blinding encompassed patients, clinicians, and outcome assessors. Recruitment spanned February 2008 to May 2014.\n\nResults: Of 404 randomized patients (202 to dexmedetomidine, 202 to placebo), 390 completed delirium assessments. The incidence of postoperative delirium was comparable between the dexmedetomidine and placebo groups (12.2% vs 11.4%, P = .94). Adjusted analyses for age and education level showed no significant differences in cognitive performance at 3 and 6 months postoperatively. Adverse events were similarly distributed between groups.\n\nInterpretation: Intraoperative dexmedetomidine does not prevent postoperative delirium, differing from previous findings in intensive care settings. The timing of administration may be critical for efficacy. Trial registration: NCT00561678. Funding: Not specified.",
  "word_count": 230
}